Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 150

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 150
---
 if DiamiR cannot obtain acceptable substitute materials, an interruption in test processing
and services could occur. Any such interruption may directly impact DiamiR’s revenue and cause DiamiR to incur higher costs.

If DiamiR cannot enter into and maintain new clinical collaborations, its efforts to commercialize CogniMIR ® and its development of other products could be delayed.

DiamiR currently has several ongoing collaborations with highly regarded
academic institutions in the NDs field. DiamiR’s success in the future may depend in part on its ability to enter into agreements
with other leading institutions in the NDs field. In the process of seeking clinical collaborations in the future DiamiR expects to engage
in discussions with third parties, which may or may not lead to collaborations.

If DiamiR’s clinical tests do not perform as expected in its validation studies, DiamiR may not be able to achieve widespread market adoption among physicians, which would cause its operating results, reputation, and business to suffer.

There is no guarantee that the accuracy and reproducibility DiamiR
has demonstrated to date will continue in its planned clinical validation studies. As a result, the failure of DiamiR’s products
to perform as expected would significantly impair its operating results and its reputation. DiamiR may be subject to legal claims arising
from any defects or errors in its clinical services tests.

DiamiR’s ability to commercialize the diagnostic products that DiamiR develops is dependent on its relationships with laboratory services providers and support of its products.

DiamiR relies on third-party providers to draw the donor blood samples
and prepare plasma in accordance with its protocol. DiamiR’s business will suffer if these service providers do not support CogniMIR
or the other products that DiamiR may develop. A lack of acceptance of DiamiR’s products by these service providers could result
in lower test volume. DiamiR’s business may suffer from the repetition of the process and increased costs.

DiamiR intends to market some of its tests as LDTs, and future changes in FDA enforcement discretion for LDTs could subject its operations to much more significant regulatory requirements.

The FDA has historically operated under a policy of enforcement discretion
with respect to LDTs whereby the FDA did not actively enforce its regulatory requirements for such tests. Changes to this policy could
significantly increase the costs and expenses of conducting, or otherwise harm, DiamiR’s business, financial condition and results
of operations. Even if such